Back-to-school eye exams: A critical window for myopia management

The back-to-school season is one of the busiest times of the year in optometric practice, particularly for clinicians caring for pediatric and adolescent patients. While families prepare for a new school year, new schedules, and extracurricular activities, eye care professionals have an equally important opportunity: to identify children at risk for myopia progression and initiate conversations about proactive management.

The start of a new academic year represents far more than updating a glasses prescription. It offers clinicians an opportunity to establish a visual baseline, evaluate refractive trajectories, educate families, and implement evidence-based interventions that may reduce the lifelong burden of progressive myopia or pivot from treatment to treatment.^1-3

As the prevalence of myopia continues to increase worldwide, back-to-school examinations have become one of the most valuable preventive visits in pediatric eye care. Rather than simply correcting blurred vision, today's optometrist is uniquely positioned to preserve long-term ocular health by slowing axial elongation before irreversible structural changes occur.^2-5

Every age brings a different opportunity

The visual needs of children evolve rapidly throughout childhood and adolescence.¹

For children entering preschool or kindergarten, comprehensive eye examinations establish an important baseline. This is often the first opportunity to discuss visual development with parents and explain how increasing educational demands can influence refractive development. Children beginning formal education experience substantially greater periods of sustained near work than ever before, making early education particularly valuable but also more visually demanding.¹

For elementary and middle school students, the conversation shifts toward risk assessment. Family history of myopia, age of onset, ethnicity, lifestyle habits, and time spent outdoors all contribute to understanding an individual child's likelihood of progression. Children who are already myopic deserve more than annual prescription updates: They deserve discussions about slowing progression through evidence-based treatment.^6,7

High school and college students experience increasingly intensive visual demands. Extended smart device use, digital learning, and intensive studying often coincide with ongoing axial elongation. Although myopia progression typically slows with age, treatment should not automatically be discontinued simply because a child reaches adolescence. Continued monitoring remains essential until refractive stability is confirmed.¹

The evolution of spectacle lenses

For decades, single-vision spectacles represented the standard of care for childhood myopia. These lenses restored clear vision but did little to influence the underlying disease process.^1,4

Earlier attempts to slow progression with executive bifocals and progressive addition lenses produced inconsistent clinical results and therefore saw limited adoption. As our understanding of peripheral retinal defocus evolved, so did spectacle lens technology.^8,9

Today's myopia-control spectacle lenses represent a fundamentally different approach. Rather than simply correcting central vision, these designs simultaneously deliver clear central vision while creating peripheral myopic defocus where light focuses slightly in front of the retina. This is intended to reduce the stimulus for axial elongation.^10,11

This evolution has transformed spectacles from passive vision correction into an active treatment modality.

What evidence shows

The primary objective of modern myopia management is not simply reducing refractive progression but slowing axial elongation to reduce the chances of structural change associated with an increased lifetime risk of retinal detachment, myopic maculopathy, glaucoma, and cataract.

Several landmark randomized clinical trials have demonstrated that specially designed spectacle lenses can significantly reduce both refractive progression and axial elongation.

Although not currently available in the United States, the Defocus Incorporated Multiple Segments spectacle lens demonstrated an approximately 52% reduction in refractive myopia progression and a 62% reduction in axial elongation over 2 years compared with single-vision lenses.¹²

Similarly, highly aspherical lenslet spectacle lenses, which are available in the United States, have demonstrated clinically meaningful reductions in both myopia progression and axial elongation in randomized controlled trials, with treatment benefits maintained over multiple years.¹¹

Equally important, studies have shown that children generally adapt well to these lenses without compromising visual acuity or overall visual performance in everyday activities.¹²

As evidence continues to accumulate, spectacle-based myopia management has become an increasingly important component of contemporary pediatric eye care.

Have myopia management spectacles entered the mainstream?

The answer is increasingly yes, but with important caveats.

Myopia-control spectacle lenses offer several practical advantages. They are noninvasive, making them an appealing option for younger children and families who may be hesitant about contact lenses. Because they are worn like conventional spectacles, they are familiar to patients and relatively straightforward to dispense, although optimal performance depends on precise measurements, careful frame selection, and accurate lens centration. For children who already wear glasses full-time, transitioning to a therapeutic spectacle lens is typically seamless and requires no additional handling beyond routine spectacle wear.

Spectacle lenses also provide flexibility. Depending on lifestyle and visual demands, some patients may alternate between therapeutic spectacles and peripheral defocus contact lenses, although treatment plans should be individualized.¹

However, barriers remain. For example, treatment success depends heavily on consistent wear. Children who frequently remove their glasses, lose them, or wear them only during classroom instruction may not receive the full therapeutic benefit observed in clinical trials.^11,12

Cost also continues to limit accessibility. Insurance reimbursement remains inconsistent, particularly within publicly funded plans, requiring many families to pay out-of-pocket for treatment. Additionally, some lens designs have prescribing limitations for higher levels of myopia or significant astigmatism.¹

These realities reinforce an important principle: No single treatment is appropriate for every child.¹

Instead, spectacle lenses should be viewed as one component of a comprehensive myopia management toolbox that also includes low-dose atropine, orthokeratology, peripheral-defocus soft contact lenses, and lifestyle modification.^1,3

The best treatment remains the one that the child will consistently use. Equally important is setting realistic expectations. Current therapies slow progression, but they do not stop myopia completely.^1,3,4

Identifying children at risk during back-to-school exams

Back-to-school examinations should extend beyond determining refractive error.

A detailed family history remains invaluable. Children with one or both myopic parents have a substantially greater risk of developing progressive myopia, particularly when onset occurs before aged 10 years.

Age of onset deserves careful attention because earlier onset is consistently associated with greater ultimate myopic severity.¹

Axial length measurement, while not absolutely required for initiating treatment, provides an objective biomarker that complements refractive findings and helps clinicians distinguish true disease progression from refractive variability. When available, serial axial length measurements can identify accelerated growth even before significant refractive changes become apparent.¹³

Lifestyle factors should also become routine discussion points.

Less time outdoors, prolonged near work, short reading distance, digital device use, and educational demands all contribute to the environmental risk profile for myopia development and progression.^6,7

Visual hygiene deserves the same emphasis we routinely place on dental hygiene. Healthy habits established during childhood often persist throughout life.¹

Adherence: The difference between treatment and success

Even the most effective therapy cannot work if children do not use it consistently.^1,11

Successful myopia management requires educating both children and parents about why treatment matters. Rather than explaining that glasses simply "help you see," clinicians can explain that these lenses are intended to protect the eyes by slowing undesirable anatomical growth.¹

Children often respond positively when they understand that treatment protects their future vision rather than merely improving today's classroom performance.¹

Parents remain equally important partners. Regular follow-up, reinforcement of full-time wear, and addressing barriers such as comfort, appearance, or peer acceptance all improve long-term adherence.^1,3

The conversation should shift from prescription renewal to disease management.

Lifestyle counseling: The often-overlooked treatment

Lifestyle modification remains one of the simplest yet most impactful interventions available.

Multiple studies demonstrate that increased outdoor time reduces the incidence of myopia in children, likely through higher ambient light exposure and reduced prolonged near work.^6,7,14

Practical recommendations are often more effective than generic advice. Families benefit from discussing realistic ways to increase outdoor activities during colder months, busy school schedules, or extracurricular seasons.

Reading should be encouraged but should be performed with optimal visual hygiene.

Maintaining appropriate working distance, taking regular visual breaks, and avoiding prolonged uninterrupted near work may help reduce accommodative stress. Audiobooks, reading outdoors, and alternating near tasks with distance activities can provide useful variety.¹⁵

Screen habits also deserve attention. Encouraging larger displays positioned farther away rather than prolonged handheld device use may reduce sustained accommodative demand, although continued research is needed.^1,6

Managing progression during growth spurts

Rapid physical growth often parallels periods of accelerated ocular growth.^1,13 Monitoring progression becomes particularly important during these years. Children demonstrating faster-than-expected axial elongation or refractive progression may require earlier intervention or treatment escalation.^1,4

Clinicians should recognize that inadequate response does not necessarily represent treatment failure. Instead, it may indicate that additional intervention is warranted.¹

Combination therapy—including optical treatment alongside low-dose atropine—is increasingly considered for children whose disease is rapidly progressing, although treatment should always be individualized based on clinical findings, patient preference, and available evidence.^16,17

Individualized care has become one of the defining characteristics of modern myopia management.

Looking ahead

Spectacle-based myopia management has evolved from an emerging technology to an increasingly accepted component of evidence-based pediatric eye care.

As additional lens designs become available and clinical experience grows, therapeutic spectacle lenses may become an increasingly common first-line option for many children developing myopia.

The back-to-school season remains one of the most important opportunities for early intervention. Every examination offers clinicians a chance not only to improve vision today but also to influence lifelong ocular health.

Ultimately, successful myopia management extends beyond selecting the appropriate optical treatment: It requires thoughtful risk assessment, patient education, adherence monitoring, lifestyle counseling, and individualized follow-up.

When these elements work together, optometrists become far more than providers of spectacles: They become lifelong advocates for children's vision and ocular health.^1,11,12

References

1. Gifford KL, Richdale K, Kang P, et al. IMI - Clinical Management Guidelines Report. Invest Ophthalmol Vis Sci. 2019;60(3):M184-M203. doi:10.1167/iovs.18-25977

2. Flitcroft DI, He M, Jonas JB, et al. IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20-M30. doi:10.1167/iovs.18-25957

3. Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2011;(12):CD004916. doi:10.1002/14651858.CD004916.pub3

4. Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci. 2019;96(6):463-465. doi:10.1097/OPX.0000000000001367

5. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006

6. Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res. 2018;62:134-149. doi:10.1016/j.preteyeres.2017.09.004

7. Rose KA, Morgan IG, Ip J, et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115(8):1279-1285. doi:10.1016/j.ophtha.2007.12.019

8. Gwiazda J, Hyman L, Hussein M, et al. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003;44(4):1492-1500. doi:10.1167/iovs.02-0816

9. Cheng D, Woo GC, Drobe B, Schmid KL. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: three-year results of a randomized clinical trial. JAMA Ophthalmol. 2014;132(3):258-264. doi:10.1001/jamaophthalmol.2013.7623

10. Smith EL 3rd. Prentice Award Lecture 2010: a case for peripheral optical treatment strategies for myopia. Optom Vis Sci. 2011;88(9):1029-1044. doi:10.1097/OPX.0b013e3182279cfa

11. Bao J, Yang A, Huang Y, et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022;106(8):1171-1176. doi:10.1136/bjophthalmol-2020-318367

12. Lam CSY, Tang WC, Tse DYY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368. doi:10.1136/bjophthalmol-2018-313739

13. Tideman JWL, Polling JR, Vingerling JR, et al. Axial length growth and the risk of developing myopia in European children. Acta Ophthalmol. 2018;96(3):301-309. doi:10.1111/aos.13603

14. Xiong S, Sankaridurg P, Naduvilath T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017;95(6):551-566. doi:10.1111/aos.13403

15. Huang HM, Chang DST, Wu PC. The association between near work activities and myopia in children-a systematic review and meta-analysis. PLoS One. 2015;10(10):e0140419. doi:10.1371/journal.pone.0140419

16. Tong L, Huang XL, Koh ALT, Zhang X, Tan DTH, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116(3):572-579. doi:10.1016/j.ophtha.2008.10.020

17. Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391-399. doi:10.1016/j.ophtha.2015.07.004